Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy.
A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
The combination of abemaciclib plus pembrolizumab is safe and effective in women with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer.
Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer
The combination of the PD-1 inhibitor pembrolizumab plus either doxorubicin or an aromatase inhibitor may be a feasible approach to treating triple-negative or hormone receptor (HR)-positive metastatic breast cancer.
Abemaciclib demonstrated efficacy and an acceptable safety profile in treating brain metastases in hormone receptor (HR)-positive/HER2-negative breast cancer, but was not effective for brain metastases in HR-positive/HER2-positive breast cancer.
Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis
The addition of Ra-223 to hormonal therapy and denosumab is a feasible and safe combination therapy in patients with hormone receptor (HR)-positive breast cancer with bone-dominant metastasis.
Efficacy and Safety of Abemaciclib in Patients with Liver Metastases in the MONARCH 1, 2, and 3 Studies
The combination of abemaciclib plus endocrine therapy is an effective treatment option in patients with hormone receptor–positive, HER2-negative advanced breast cancer with liver metastases, with significantly higher clinical benefits than those derived from single-agent endocrine therapy.
The Benefit of Abemaciclib in Prognostic Subgroups: An Exploratory Analysis of Combined Data from MONARCH 2 and 3
In a subanalysis of the MONARCH 2 and 3 studies, patients with hormone receptor–positive, HER2-negative breast cancer with poor prognostic factors received greater benefit from the addition of abemaciclib to endocrine therapy than those without a poor prognosis.
The Synergistic Antitumor Activity of Entinostat (MS-275) in Combination with Palbociclib (PD 0332991) in ER-Positive and TN Breast Cancer
The combination of the selective histone deacetylase inhibitor entinostat plus a CDK4/6 inhibitor demonstrates greater synergistic antitumor activity against estrogen receptor (ER)-positive breast cancer and triple-negative (TN) breast cancer than either agent alone.
MonarchE is an ongoing, open-label phase 3 study designed to evaluate invasive disease-free survival in patients with hormone receptor‒positive, HER2-negative advanced breast cancer receiving abemaciclib plus standard-of-care adjuvant endocrine therapy (ET).
Page 3 of 4
Results 21 - 30 of 32
Results 21 - 30 of 32